Optiver Holding
RAPP

Optiver Holding’s Rapport Therapeutics RAPP Stock Holding History

Optiver Holding’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25K Sell
54
-150
-74% -$5.51K ﹤0.01% 2277
2026
Q1 		$6.38K Buy
204
+132
+183% +$3.71K ﹤0.01% 1336
2025
Q4 		$2.18K Sell
72
-34
-32% -$941 ﹤0.01% 1969
2025
Q3 		$3.15K Buy
+106
New +$1.89K ﹤0.01% 2152

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Optiver Holding's RAPP Position: Q2 2026 in Review

Optiver Holding reduced its Rapport Therapeutics (RAPP) stake by 74% in Q2 2026, selling an estimated $5.51K and leaving 54 shares worth $2.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Optiver Holding first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.38K in Q1 2026. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Optiver Holding held 54 shares of Rapport Therapeutics worth $2.25K as of Q2 2026.
  • Optiver Holding sold 150 Rapport Therapeutics shares in Q2 2026, an estimated $5.51K.
  • Rapport Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2277 holding.
  • Optiver Holding first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Rapport Therapeutics position peaked at $6.38K in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.